Most-Upgraded StocksMost-UpgradedNASDAQ:RVMD Revolution Medicines (RVMD) Stock Price, News & Analysis $204.86 -0.25 (-0.12%) Closing price 09/15/2026 04:00 PM EasternExtended Trading$204.94 +0.08 (+0.04%) As of 09/15/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Revolution Medicines Stock (NASDAQ:RVMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Revolution Medicines alerts:Sign Up Key Stats Today's Range$200.24▼$207.0050-Day Range$179.18▼$221.1552-Week Range$42.18▼$224.31Volume1.27 million shsAverage Volume1.65 million shsMarket Capitalization$43.91 billionP/E RatioN/ADividend YieldN/APrice Target$226.17Consensus RatingModerate Buy Company Overview Revolution Medicines, Inc. is a clinical-stage biotechnology company focused on developing targeted treatments for cancer. The company specializes in therapies designed to inhibit oncogenic RAS signaling, a pathway involved in many difficult-to-treat cancers, including tumors driven by KRAS mutations. Its pipeline includes investigational RAS(ON) inhibitors intended to target active forms of RAS proteins. Key programs have included daraxonrasib (RMC-6236), an oral inhibitor being studied in cancers with a range of RAS mutations, as well as mutation-selective programs such as RMC-9805 for KRAS G12D and RMC-6291 for KRAS G12C. These candidates remain under clinical development and are not approved products. Founded in 2014 and headquartered in Redwood City, California, Revolution Medicines conducts research and clinical development activities through collaborations and clinical studies in the United States and internationally. The company is led by Mark A. Goldsmith, who serves as chairman and chief executive officer. Revolution Medicines does not currently have commercially marketed medicines.AI Generated. May Contain Errors. Read More Revolution Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreRVMD MarketRank™: Revolution Medicines scored higher than 58% of companies evaluated by MarketBeat, and ranked 401st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingRevolution Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 2 strong buy ratings, 17 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialRevolution Medicines has a consensus price target of $226.17, representing about 10.4% upside from its current price of $204.86.Amount of Analyst CoverageRevolution Medicines has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Revolution Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Revolution Medicines are expected to grow in the coming year, from ($8.87) to ($6.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revolution Medicines is -23.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revolution Medicines is -23.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRevolution Medicines has a P/B Ratio of 24.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Revolution Medicines' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.91% of the float of Revolution Medicines has been sold short.Short Interest Ratio / Days to CoverRevolution Medicines has a short interest ratio ("days to cover") of 4.69.Change versus previous monthShort interest in Revolution Medicines has recently increased by 0.10%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRevolution Medicines does not currently pay a dividend.Dividend GrowthRevolution Medicines does not have a long track record of dividend growth. News and Social Media4.3 / 5News Sentiment0.92 News SentimentRevolution Medicines has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Revolution Medicines this week, compared to 9 articles on an average week.Search Interest37 people have searched for RVMD on MarketBeat in the last 30 days. This is an increase of 37% compared to the previous 30 days.MarketBeat Follows22 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 120% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $71,898,323.00 in company stock.Percentage Held by Insiders7.60% of the stock of Revolution Medicines is held by insiders.Percentage Held by Institutions94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Revolution Medicines' insider trading history. Receive RVMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RVMD Stock News HeadlinesRevolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic CancerSeptember 14 at 8:40 PM | finance.yahoo.comRevolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic CancerSeptember 14 at 4:05 PM | globenewswire.comGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low. Beijing's central bank has bought gold for 20 straight months, its longest streak in a decade. Goldman Sachs estimates China's real gold buying is 4.8 times the official figure. The European Central Bank confirms gold has overtaken US Treasuries as the world's top reserve asset, at 27% versus 22%. As foreign demand for US debt fades, rates and everyday costs may feel the pressure. | Behind the Markets (Ad)MarketBeat Week in Review – 09/07 - 09/11 (RVMD)Stocks fell this week on oil prices and Fed rate-hike expectations, though Oracle's earnings underscored AI infrastructure strength. MarketBeat analysts recap top stories on earnings, defense, AI, and other stock opportunities.September 12 at 7:00 AM | marketbeat.comRevolution Medicines (RVMD) Gets its First Approved Drug, and the Market ShrugsSeptember 11, 2026 | insidermonkey.comLorence Kim Sells 17,090 Shares of Revolution Medicines (NASDAQ:RVMD) StockSeptember 11, 2026 | insidertrades.comRevolution Medicines Got Its Breakthrough—What Moves It Next?FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.September 4, 2026 | marketbeat.comRevolution Medicines (NASDAQ:RVMD) Director Lorence Kim Sells 56,000 SharesSeptember 3, 2026 | insidertrades.comSee More Headlines RVMD Stock Analysis - Frequently Asked Questions How have RVMD shares performed this year? Revolution Medicines' stock was trading at $79.65 at the beginning of the year. Since then, RVMD stock has increased by 157.2% and is now trading at $204.86. How were Revolution Medicines' earnings last quarter? Revolution Medicines, Inc. (NASDAQ:RVMD) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.04) by $1.02. Read the conference call transcript. When did Revolution Medicines IPO? Revolution Medicines (RVMD) raised $231 million in an initial public offering on Thursday, February 13th 2020. The company issued 14,000,000 shares at $16.00-$17.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO. Who are Revolution Medicines' major shareholders? Revolution Medicines' top institutional shareholders include Wellington Management Group LLP (1.79%), Alphabet Inc. (1.39%), Bank of America Corp DE (0.46%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.43%). Insiders that own company stock include Thilo Schroeder, Stephen Michael Kelsey, Mark A Goldsmith, Margaret A Horn, Jack Anders, Xiaolin Wang, Lin Wei, Jeff Cislini, Sushil Patel, Barbara Weber and Lorence H Kim. View institutional ownership trends. How do I buy shares of Revolution Medicines? Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Revolution Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Revolution Medicines investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/05/2026Today9/15/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 RVMD's financial health is in the Green zone, according to TradeSmith. RVMD has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RVMD CIK1628171 Webwww.revmed.com Phone650-481-6801FaxN/AEmployees883Year Founded2014Price Target and Rating Average Price Target for Revolution Medicines$226.17 High Price Target$320.00 Low Price Target$80.00 Potential Upside/Downside+10.4%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($8.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.13 billion Net MarginsN/A Pretax MarginN/A Return on Equity-88.20% Return on Assets-57.85% Debt Debt-to-Equity Ratio0.40 Current Ratio11.38 Quick Ratio11.38 Sales & Book Value Annual Sales$11.58 million Price / Sales3,791.86 Cash FlowN/A Price / Cash FlowN/A Book Value$8.44 per share Price / Book24.27Miscellaneous Outstanding Shares214,340,000Free Float198,046,000Market Cap$43.91 billion OptionableOptionable Beta1.40 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:RVMD) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersThis Microcap Is Taking On the Energy Industry’s Dirtiest ProblemsA small company has developed water-based cleaning technologies aimed at some of heavy industry's toughest pro...Wall Street Logic | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredCFA: Decentralized AI is the Next WaveDon't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...Decentralized Masters | SponsoredGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revolution Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revolution Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
